An integrative multi-omics approach to targeting cellular senescence as a drug repurposing strategy for age-related morbidities

Apply and key information  

Summary

Age is a major risk factor for various human diseases including cancers, dementia, and cardiovascular diseases. Senescence is a process where cells cease dividing and undergo distinctive phenotypic changes. Senescence has a key role in the aging process and has also been implicated as a major cause of age-related disease. The recent COVID-19 pandemic also clearly showed that age is a prominent risk factor for the severity of the disease.  Indeed SARS-CoV-2 induced senescence is not only a driver but also a therapeutic target in COVID-19. Targeting cellular senescence could potentially alleviate many age-related pathologies.

In this project, we aim to identify therapeutic candidates that could selectively eliminate senescent cells. Such drugs are often referred to as senolytics, which could contribute to the treatment of specific age-related diseases, and potentially could also improve the life and health span of aged individuals.  We propose to deploy an integrative multi-omics connectivity mapping approach to targeting cellular senescence as a drug repurposing strategy for potential applications in age-related diseases.

Our team have extensive experience and expertise in applying this data-intensive approach to several human diseases, with a catalogue of successes, in cancer [Ramsey et al2013; Wen et al2016] and cystic fibrosis [Malcomson et al 2016,PNAS]. Our innovations include a robust framework for gene expression connectivity mapping, a similarity metric ‘ZhangScore’ with superior performance [De Wolf et al 2018,PMID:29658791], and a series of computational techniques for constructing disease query gene signatures, e.g. gene signature perturbation (McArt&Zhang2011), gene signature progression (Wen et al2016), and related software tools including sscMap (Zhang&Gant2009), cudaMap (McArt et al2013) and QUADrATiC (O'Reilly et al2016). New combinations of these innovative elements and their novel applications to senescence and aging as a new area represents a big step forward in our methodological innovation and drug repurposing research.

Objectives of the research

The objectives of the research include:

1) Integration of multiple streams and categories of data in public data repositories from cellular senescence and aging related studies, as well as in-house multi-omics datasets including WGS, proteomics, and transcriptomics for 500 COVID-19 patients.

2) Construction of robust gene signatures for cellular senescence based on the integrative analysis of the multi-omics datasets.

3) Application of our established gene expression connectivity mapping framework to computationally screen a collection of over 1500 approved drugs for the identification of senolytics candidates.

Methods to be used

This is primarily a desk-based computational and bioinformatics project. The datasets to be used for integrative analysis are either from public data repositories or have already been generated in the labs of the supervisory teams.  Successful completion of this project will lay the solid foundation for a future lab-based experimental project to validate the computational findings. Bioinformatics methodology to be employed includes differential expression analysis of transcriptomics and proteomics data; Seed gene-based expression correlation analysis using known senescence genes as the seeds; Gene network and functional enrichment analysis; Gene expression connectivity mapping for computational drug screening.

Skills required of applicant

This is mainly a computational project involving the use of the state-of-art bioinformatics techniques in the processing and analysis of multi-omics datasets. The student will gain valuable exposure to basic statistics ideas as well as to useful computing techniques and tools, which are becoming increasing important for biomedical scientists in personalised medicine research.

The student is expected to have:

1.         An understanding of basic statistics ideas.

2.         Good IT skills in working with common Spreadsheet Applications, eg MS Excel

3.         Some experience with a programming language is required, preferably R or Python.

Essential criteria

Applicants should hold, or expect to obtain, a First or Upper Second Class Honours Degree in a subject relevant to the proposed area of study.

We may also consider applications from those who hold equivalent qualifications, for example, a Lower Second Class Honours Degree plus a Master’s Degree with Distinction.

In exceptional circumstances, the University may consider a portfolio of evidence from applicants who have appropriate professional experience which is equivalent to the learning outcomes of an Honours degree in lieu of academic qualifications.

  • Experience using research methods or other approaches relevant to the subject domain
  • A comprehensive and articulate personal statement
  • A demonstrable interest in the research area associated with the studentship

Desirable Criteria

If the University receives a large number of applicants for the project, the following desirable criteria may be applied to shortlist applicants for interview.

  • First Class Honours (1st) Degree
  • Use of personal initiative as evidenced by record of work above that normally expected at career stage.
  • Applicants will be shortlisted if they have an average of 75% or greater in a first (honours) degree (or a GPA of 8.75/10). For applicants with a first degree average in the range of 70% to 74% (GPA 3.3): If they are undertaking an Masters, then the average of their first degree marks and their Masters marks will be used for shortlisting.
  • Relevant professional qualification and/or a Degree in a Health or Health related area

Equal Opportunities

The University is an equal opportunities employer and welcomes applicants from all sections of the community, particularly from those with disabilities.

Appointment will be made on merit.

Funding and eligibility

Recommended reading

  1. Al-Natour  B et al. 2021. PubMed Article ID PMID:33964033. Identification and validation  of novel biomarkers and therapeutics for pulpitis using connectivity mapping.  doi:10.1111/iej.13547
  2. De Wolf H et al.  2018. PMID:29658791.  High-Throughput Gene Expression Profiles to Define Drug Similarity and Predict  Compound Activity. doi:10.1089/adt.2018.845
  3. Guo G et al. 2021.  PMID: 34023420. The  role of senescence in the pathogenesis of atrial fibrillation: A target  process for health improvement and drug development. doi:  10.1016/j.arr.2021.101363.
  4. Lamb J et al. 2006.  PMID:17008526. The  Connectivity Map: using gene-expression signatures to connect small molecules,  genes, and disease. doi:10.1126/science.1132939
  5. Lee  S et al. 2021. PMID: 34517409. Virus-induced senescence is a driver and  therapeutic target in COVID-19. Nature. 2021 Nov;599(7884):283-289. doi:  10.1038/s41586-021-03995-1.
  6. Lin K et al. 2020.  PMID:31774912. A  comprehensive evaluation of connectivity methods for L1000 data.  doi:10.1093/bib/bbz129
  7. Li Z et al. 2022.  PMID:35417037. Transcriptome‑based  drug repositioning identifies TPCA‑1 as a potential  selective inhibitor of esophagus squamous carcinoma cell viability.  doi:10.3892/ijmm.2022.5131
  8. Lynch SM et al 2021.  PMID: 34943875. Role  of Senescence and Aging in SARS-CoV-2 Infection and COVID-19 Disease. doi:  10.3390/cells10123367.
  9. Malcomson B et al.  2016. PMID:27286825. Connectivity  mapping (ssCMap) to predict A20-inducing drugs and their antiinflammatory  action in cystic fibrosis. doi:10.1073/pnas.1520289113
  10. McArt DG et al. 2011.  PMID:21305029. Identification  of candidate small-molecule therapeutics to cancer by gene-signature  perturbation in connectivity mapping. doi:10.1371/journal.pone.0016382
  11. McArt DG et al. 2013.  PMID:23840550. Connectivity  Mapping for Candidate Therapeutics Identification Using Next Generation  Sequencing RNA-Seq Data. doi:10.1371/journal.pone.0066902
  12. McArt  DG et al. 2013. PMID:24112435. cudaMap: a GPU accelerated program for gene  expression connectivity mapping. doi:10.1186/1471-2105-14-305
  13. McHugh  D, Gil J. 2018. PMID: 29114066. Senescence and aging: Causes, consequences,  and therapeutic avenues. doi: 10.1083/jcb.201708092.
  14. O'Reilly PG et al.  2016. PMID:27143038. QUADrATiC:  scalable gene expression connectivity mapping for repurposing FDA-approved  therapeutics. doi:10.1186/s12859-016-1062-1
  15. Ramsey JM et al.  2013. PMID:23592435. Entinostat  prevents leukemia maintenance in a collaborating oncogene-dependent model of  cytogenetically normal acute myeloid leukemia. doi:10.1002/stem.1398
  16. Subramanian  A et al. 2017. PMID:29195078. A Next Generation Connectivity Map: L1000  Platform and the First 1,000,000 Profiles. doi:10.1016/j.cell.2017.10.049
  17. Wen Q et al. 2015.  PMID:26356760. Connectivity  mapping using a combined gene signature from multiple colorectal cancer  datasets identified candidate drugs including existing chemotherapies.  doi:10.1186/1752-0509-9-S5-S4
  18. Wen Q et al. 2016.  PMID:27170106. A  gene-signature progression approach to identifying candidate small-molecule  cancer therapeutics with connectivity mapping. doi:10.1186/s12859-016-1066-x
  19. Wen Q et al. 2017.  PMID:27965461. KRAS  mutant colorectal cancer gene signatures identified angiotensin II receptor  blockers as potential therapies. doi:10.18632/oncotarget.13884
  20. van  Deursen JM. 2014. PMID: 24848057. The role of senescent cells in ageing. doi:  10.1038/nature13193.
  21. Zhang SD et al. 2008.  PMID:18518950. A  simple and robust method for connecting small-molecule drugs using  gene-expression signatures. doi:10.1186/1471-2105-9-258
  22. Zhang  SD et al. 2009. PMID:19646231. sscMap: an extensible Java application for  connecting small-molecule drugs using gene-expression signatures.  doi:10.1186/1471-2105-10-236

The Doctoral College at Ulster University

Key dates

Submission deadline
Friday 2 August 2024
04:00PM

Interview Date
Early August 2024

Preferred student start date
16 September 2024

Applying

Apply Online  

Contact supervisor

Dr Shu-Dong Zhang

Other supervisors